Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

TOP - April 2010 Vol 3, No 2

One third of patients with newly diagnosed, advanced chronic lymphocytic leukemia (CLL) who received the combination of bendamustine and rituximab achieved a complete response, according to researchers from the German CLL Study Group.

Although thrombocytopenia is a common problem in patients with cancer, idiopathic thrombocytopenic purpura (ITP) is relatively rare and is difficult to treat when duration exceeds 6 months. ITP can be either acute (duration ≤6 months) or chronic, can occur in both adults and children, and can be primary or secondary to another disorder, including the malignancy.

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome (Ph), which is formed by genetic exchange between chromosomes 9 and 22 and codes for the pathogenic tyrosine kinase BCR-ABL.1-3 Historically, therapeutic interventions for CML have included busulfan, hydroxyurea, interferon-a, and stem cell transplantation.4 These therapies vary greatly in tolerability, toxicity, and efficacy.

Page 2 of 2
Results 11 - 13 of 13